Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955315 | 0.92 | ALDH1A1 (0.33) | ALDH1A1NPSR1LMNAKDM4EMEN1 | |
| SCHEMBL9131554 | 0.83 | AGTR2 (0.32) | AGTR2 | |
| SCHEMBL707335 | 0.80 | AGTR2 (0.34) | AGTR2ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL9132552 | 0.76 | AGTR2 (0.48) | AGTR2 | |
| SCHEMBL9132555 | 0.75 | AGTR2 (0.38) | AGTR2 | |
| SCHEMBL708647 | 0.71 | SMN1; SMN2 (0.40) | ALDH1A1LMNAKDM4EMEN1NPC1 | |
| SCHEMBL21125131 | 0.69 | NPSR1 (0.43) | ALDH1A1NPSR1LMNAKDM4EMEN1 | |
| SCHEMBL7260194 | 0.67 | EDNRB (0.38) | ALDH1A1LMNAKDM4EMEN1NPC1 | |
| SCHEMBL21124771 | 0.67 | PARG (0.40) | NPSR1LMNAKDM4EMEN1NPC1 | |
| SCHEMBL29726813 | 0.67 | PARG (0.40) | NPSR1LMNAKDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8124638-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-7652054-B2 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2010-01-26 | — | — | US | disclosed |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | VICORE PHARMA AB | 2009-12-31 | — | — | US | disclosed |
| EP-1395566-B1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
| EP-1395566-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | Vicore Pharma AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002096883-A1 | TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | AGTR2 2/4885ALDH1A1 3595/4885NPSR1 71/4885 |
| US-20090326026-A1 | Tricyclic Compounds Useful as Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885ALDH1A1 4115/4885NPSR1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.